CYP3A4和CYP3A5多形态和基因型组合的分布与塔克罗利斯代谢有关
Ibtissem Hannachi1, Zohra Chadli1, Emna Kerkeni2
1Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
La Tunisie medicale
|September 17, 2024
概括
在CYP3A4和CYP3A5中的遗传变异会影响塔克罗利的代谢. 这项研究对突尼斯人的CYP3A4*1B,CYP3A4*22和CYP3A5*3多态性进行了表征,显示中间代谢器占主导地位.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 临床遗传学 临床遗传学
背景情况:
- 细胞染色体P450酶,特别是CYP3A4和CYP3A5,对于代谢像塔克罗利斯这样的药物至关重要.
- 编码CYP3A4和CYP3A5的基因中的单核酸多态 (SNP) 会导致它们的表达和功能的显著跨种族变异.
研究的目的:
- 调查突尼斯人口中CYP3A4*1B,CYP3A4*22和CYP3A5*3的遗传多态性.
- 根据基因型组合建立新的代谢器状态 (缓慢,中等,高,广泛).
主要方法:
- 对CYP3A4和CYP3A5的基因定型使用聚合酶链反应-限制片段长度多态 (PCR-RFLP) 进行.
- 这项研究包括突尼斯的健康受试者和接受塔克罗利木斯治疗的移植受试者.
- 根据CYP3A4*1B,CYP3A4*22,CYP3A5*3.3的组合基因型定义了四种不同的代谢器状态.
主要成果:
- 在突尼斯人中占主导地位的等位基因包括野生型CYP3A4*1B (0.87),CYP3A4*22 (0.975) 和CYP3A5*3 (0.82).
- 基因型频率包括:CYP3A4*1B (3.9%),CYP3A4*22 (0.0%) 和CYP3A5*3 (69.5%). 基因型频率包括:CYP3A4*1B (3.9%),CYP3A4*22 (0.0%) 和CYP3A5*3 (69.5%). 基因型频率包括:
- 中级代谢者 (IM) 是主要的表型 (124名患者),其次是广泛代谢者 (EM) (41名患者).
结论:
- 突尼斯人中CYP3A4*1B,CYP3A4*22和CYP3A5*3的遗传特征对于个性化医疗非常重要.
- 这些发现表明,突尼斯人口对这些CYP多态的遗传构成与高加索人相似.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103
Factors Affecting Drug Biotransformation: Biological
125
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
125
Nonlinear Pharmacokinetics: Role of Transporters
40
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
40
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34
Hepatic Drug Clearance: Role of Transporters
44
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
44
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


